Viewing Study NCT06709859


Ignite Creation Date: 2025-12-24 @ 2:32 PM
Ignite Modification Date: 2026-01-11 @ 7:48 AM
Study NCT ID: NCT06709859
Status: RECRUITING
Last Update Posted: 2025-07-17
First Post: 2024-11-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Sponsor: Shandong Public Health Clinical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module